Komori
Iida Group Holdings (3291) · FactReframed

Research and development expenses of ¥162 million for the cumulative period through the third quarter

First written in FY2019-Q3. 25 of 26 entries say "Reframed", first in FY2019. Latest entry: FY2027-H1.

26entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseReframedFY2019 – FY2027-H12019: 420192020: 420202021: 320212022: 420222023: 420232024: 320242025: 220252026: 22026
Same theme, other companies
Recognition and Disclosure of R&D ExpensesA theme 80 companies write about · 0 as a headwind · 23 as a tailwind

Iida Group Holdings moved to the "Worse" side of this theme in 2020.

1 other company's latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 80 companies compared. The sentences above are computed from all 80.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1ReframedAnnual report

    「Group-wide research and development expenses for the interim consolidated accounting period were ¥221 million.」

    The period covered by research and development expenses was updated to the interim consolidated accounting period, and the amount was ¥221 million.
  2. FY2026ReframedAnnual report

    「Group-wide research and development expenses for the current consolidated fiscal year are ¥576 million.」

    The period and amount covered by the research and development expense disclosure have been updated from ¥830 million for the full previous fiscal year to ¥576 million for the full current fiscal year.
  3. FY2026-H1ReframedAnnual report

    「Group-wide research and development expenses for the current interim consolidated accounting period are ¥374 million.」

    The disclosure period for research and development expenses has been updated to the interim consolidated accounting period of fiscal 2025, with the amount reported at ¥374 million.
  4. FY2025ReframedAnnual report

    「Group-wide research and development expenses for the current consolidated fiscal year are ¥830 million.」

    The research and development expense disclosure has been updated from ¥665 million for fiscal 2024 to ¥830 million for fiscal 2025.
  5. FY2025-H1ReframedAnnual report

    「Group-wide research and development expenses for the current interim consolidated accounting period are ¥303 million.」

    The disclosure period for research and development expenses has been updated to the current interim consolidated accounting period, with the amount reported at ¥303 million.
  6. FY2024ReframedAnnual report

    「Group-wide research and development expenses for the current consolidated fiscal year are ¥665 million.」

    The period and amount covered by the research and development expense disclosure have been updated from ¥571 million for the full previous fiscal year to ¥665 million for the full current fiscal year.
  7. FY2024-Q3ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥490 million for the nine-month cumulative consolidated period.」

    The disclosure period for research and development expenses has been updated to the cumulative third-quarter period of the current fiscal year, with the amount reported at ¥490 million.
  8. FY2024-Q2ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥241 million for the six-month cumulative consolidated period.」

    The reporting subject for research and development expenses was updated to the current six-month cumulative period, at ¥241 million.
  9. FY2024-Q1ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥124 million for the first-quarter cumulative consolidated period.」

    The reporting subject for research and development expenses was updated to the current first-quarter cumulative period, at ¥124 million.
  10. FY2023ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥571 million for the consolidated fiscal year.」

    The reporting subject for research and development expenses was updated from ¥545 million for the previous full fiscal year to ¥571 million for the current full fiscal year.
  11. FY2023-Q3ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥401 million for the nine-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥257 million for the six-month cumulative period to ¥401 million for the current nine-month cumulative period.
  12. FY2023-Q2ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥257 million for the six-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥185 million for the six-month cumulative period of the previous fiscal year to ¥257 million for the six-month cumulative period of the current fiscal year.
  13. FY2023-Q1ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥114 million for the first-quarter cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥113 million for the first quarter of the previous fiscal year to ¥114 million for the first quarter of the current fiscal year.
  14. FY2022ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥545 million for the consolidated fiscal year.」

    The reporting period and amount for research and development expenses were updated from ¥358 million for the nine-month cumulative period of the previous fiscal year to ¥545 million for the current full fiscal year.
  15. FY2022-Q3ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥358 million for the nine-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥222 million for the nine-month cumulative period and ¥185 million for the six-month cumulative period of the previous fiscal year to ¥358 million for the nine-month cumulative period of the current fiscal year.
  16. FY2022-Q2ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥241 million for the six-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥185 million for the six-month cumulative period of the previous fiscal year to ¥241 million for the six-month cumulative period of the current fiscal year.
  17. FY2022-Q1ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥113 million for the first-quarter cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥112 million for the first quarter of the previous fiscal year to ¥113 million for the first quarter of the current fiscal year.
  18. FY2021-Q3ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥344 million for the nine-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥238 million for the previous quarter's cumulative period to ¥344 million for the nine-month cumulative period.
  19. FY2021-Q2ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥238 million for the six-month cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥112 million for the first-quarter cumulative period to ¥238 million for the six-month cumulative period.
  20. FY2021-Q1ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥112 million for the first-quarter cumulative consolidated period.」

    The reporting period and amount for research and development expenses were updated from ¥261 million for the previous full fiscal year to ¥112 million for the current first-quarter cumulative period.
  21. FY2020ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥261 million for the consolidated fiscal year.」

    The reporting period for research and development expenses was updated from the nine-month cumulative period, at ¥222 million, to the full fiscal year, at ¥261 million, disclosing the full-year results of research and development activities.
  22. FY2020-Q3ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥222 million for the nine-month cumulative consolidated period.」

    The reporting period for research and development expenses was updated from the six-month cumulative period, at ¥185 million, to the nine-month cumulative period, at ¥222 million.
  23. FY2020-Q2ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥185 million for the six-month cumulative consolidated period.」

    The reporting period for research and development expenses was updated from the first-quarter cumulative period, at ¥151 million, to the six-month cumulative period, at ¥185 million.
  24. FY2020-Q1ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥151 million for the first-quarter cumulative consolidated period.」

    The reporting period and amount were updated from ¥206 million for the full fiscal year to ¥151 million for the first-quarter cumulative period in research and development expenses.
  25. FY2019ReframedAnnual report

    「Research and development expenses for the Group as a whole were ¥206 million for the consolidated fiscal year.」

    The reporting period and amount were updated from ¥162 million for the nine-month cumulative period to ¥206 million for the full fiscal year in research and development expenses.
  26. FY2019-Q3First statedAnnual report

    「Research and development expenses for the Group as a whole were ¥162 million for the nine-month cumulative consolidated period.」

    The Group disclosed research and development expenses for the nine-month cumulative consolidated period.
Moved together

"Revenue and Sales Volume by Business Category for the First Quarter of the Seventh Fiscal Period" moved the same way as this thread, in the same document, in 22 of its 26 moves.

222019171515★123456
  1. ★This thread
  2. 1Revenue and Sales Volume by Business Category for the First Quarter of the Seventh Fiscal Period22×
  3. 2Improvement in Employment and Income Conditions and a Gradual Recovery in the Domestic Economy20×
  4. 3Reliance on Borrowings and Financing and Interest Rate Fluctuation Risks19×
  5. 4Fiscal 2016 First-Quarter Revenue and Earnings Growth17×
  6. 5Slowdown in Overseas Economies and Uncertainty over Economic Conditions in Europe15×
  7. 6Pressure on Operating Cash Flow from Increased Inventories15×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Iida Group Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.